Effects of experimental sleep deprivation on anxiety-like behavior in animal research: Systematic review and meta-analysis

Pires, Gabriel Natan; Bezerra, Andréia Gomes; Tufik, Sérgio; Andersen, Mônica Levy

doi:10.1016/j.neubiorev.2016.06.028

Cited by 58 publications

(40 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, Pava et al (2016) used rotating disk paradigm for sleep deprivation studies whereas in the current report, gentle manipulation was handled. Differences in techniques used for sleep deprivation have provided different outcomes in intensity of sleep rebound (Rechtschaffen et al, 1999;Colavito et al, 2013;Pires et al, 2016). Additionally, the pharmacodynamics between the compounds might exert influence on the Fig.…”

Section: Discussionmentioning

confidence: 99%

Revealing the role of the endocannabinoid system modulators, SR141716A, URB597 and VDM-11, in sleep homeostasis

et al. 2016

View full text Add to dashboard Cite

Abstract-The endocannabinoid system comprises receptors (CB 1 and CB 2 cannabinoid receptors), enzymes (Fatty Acid Amide Hydrolase [FAAH], which synthesizes the endocannabinoid anandamide), as well as the anandamide membrane transporter (AMT). Importantly, previous experiments have demonstrated that the endocannabinoid system modulates multiple neurobiological functions, including sleep. For instance, SR141716A (the CB 1 cannabinoid receptor antagonist) as well as URB597 (the FAAH inhibitor) increase waking in rats whereas VDM-11 (the blocker of the AMT) enhances sleep in rodents. However, no further evidence is available regarding the neurobiological role of the endocannabinoid system in the homeostatic control of sleep. Therefore, the aim of the current experiment was to test if SR141716A, URB597 or VDM-11 would modulate the sleep rebound after sleep deprivation. Thus, these compounds were systemically injected (5, 10, 20 mg/kg; ip; separately each one) into rats after prolonged waking. We found that SR141716A and URB597 blocked in dose-dependent fashion the sleep rebound whereas animals treated with VDM-11 displayed sleep rebound during the recovery period. Complementary, injection after sleep deprivation of either SR141716A or URB597 enhanced dose-dependently the extracellular levels of dopamine (DA), norepinephrine (NE), epinephrine (EP), serotonin (5-HT), as well as adenosine (AD) while VDM-11 caused a decline in contents of these molecules. These findings suggest that SR141716A or URB597 behave as a potent stimulants since they suppressed the sleep recovery period after prolonged waking. It can be concluded that elements of the endocannabinoid system, such as the CB 1 cannabinoid receptor, FAAH and AMT, modulate the sleep homeostasis after prolonged waking. Ó

show abstract

Section: Discussionmentioning

confidence: 99%

Revealing the role of the endocannabinoid system modulators, SR141716A, URB597 and VDM-11, in sleep homeostasis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…As a crude measure of study (reporting) quality, we calculated percentages of reported study characteristics for our sample of studies. We created a list of characteristics based on the SYRCLE risk of bias tool [38], adapted it to sleep studies as partially described before [39], and added specific elements for microdialysis studies, as described in appendix 4.…”

Section: Methodsmentioning

confidence: 99%

Brain Microdialysate Monoamines in Relation to Circadian Rhythms, Sleep, and Sleep Deprivation – a Systematic Review, Network Meta-analysis, and New Primary Data

Menon¹,

Nolten²,

Achterberg³

et al. 2019

Journal of Circadian Rhythms

View full text Add to dashboard Cite

Disruption of the monoaminergic system, e.g. by sleep deprivation (SD), seems to promote certain diseases. Assessment of monoamine levels over the circadian cycle, during different sleep stages and during SD is instrumental to understand the molecular dynamics during and after SD. To provide a complete overview of all available evidence, we performed a systematic review. A comprehensive search was performed for microdialysis and certain monoamines (dopamine, serotonin, noradrenaline, adrenaline), certain monoamine metabolites (3,4-dihydroxyphenylacetic acid (DOPAC), 5-hydroxyindoleacetic acid (5-HIAA)) and a precursor (5-hydroxytryptophan (5-HTP)) in PubMed and EMBASE. After screening of the search results by two independent reviewers, 94 publications were included. All results were tabulated and described qualitatively. Network-meta analyses (NMAs) were performed to compare noradrenaline and serotonin concentrations between sleep stages. We further present experimental monoamine data from the medial prefrontal cortical (mPFC). Monoamine levels varied with brain region and circadian cycle. During sleep, monoamine levels generally decreased compared to wake. These qualitative observations were supported by the NMAs: noradrenaline and serotonin levels decreased from wakefulness to slow wave sleep and decreased further during Rapid Eye Movement sleep. In contrast, monoamine levels generally increased during SD, and sometimes remained high even during subsequent recovery. Decreases during or after SD were only reported for serotonin. In our experiment, SD did not affect any of the mPFC monoamine levels. Concluding, monoamine levels vary over the light-dark cycle and between sleep stages. SD modifies the patterns, with effects sometimes lasting beyond the SD period.

show abstract

“…However, SD in addition to its antidepressant effects also induces impairments in cognitive functions similar to those of ethanol which also induces an up‐regulation of cerebral A 1 adenosine receptors (Elmenhorst et al, ). In addition, SD in humans appears to increase state anxiety (Pires et al, ), but may induce rather a decrease in anxiety‐like behavior in preclinical models (Pires et al, ). There are differences in the time courses for impairment of performance and recovery between acute and chronic sleep loss.…”

Section: Role Of Adenosine Receptors In the Effects Of Sd And Chronicmentioning

confidence: 99%

The role of adenosine receptors in mood and anxiety disorders

Calker

Biber

Domschke

et al. 2019

Journal of Neurochemistry

View full text Add to dashboard Cite

Adenosine receptor subtypes, first described 40 years ago, are known to regulate diverse biological functions and have a role in various conditions, such as cerebral and cardiac ischemia, immune and inflammatory disorders and cancer. In the brain, they limit potentially dangerous over excitation, but also regulate mechanisms essential in sleep and psychiatric disorders. In this review, we discuss the role of adenosine receptors in mood and anxiety disorders. Activation of A 2A receptors is associated with increased depression-like symptoms, while increased A 1 receptors signaling elicits rapid antidepressant effects. Indeed, several lines of evidence demonstrate that the therapeutic effects of different non-pharmacological treatments of depression, like sleep deprivation and electroconvulsive therapy are mediated by A 1 receptor up-regulation or activation. In addition, A 1 receptors may also play a role in the antidepressant effects of transcranial direct current stimulation and deep brain stimulation. As a potential downstream mechanism, which facilitates the antidepressant effects of A 1 receptors, we propose a crosstalk between adenosinergic and glutamatergic systems mediated via synaptic plasticity protein Homer1a and a-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Moreover, adenosine receptors are also involved in the control of circadian rhythms, sleep homeostasis and some neuroimmunological mechanisms, all of them implicated in mood regulation. Antagonists of adenosine receptors such as caffeine have general anxiogenic effects. In particular, A 2A receptors appear to have an important role in the pathophysiology of anxiety disorders. Taken together, the results discussed here indicate that the adenosinergic system is involved in both the etiology and the treatment of mood and anxiety disorders.

show abstract

Effects of experimental sleep deprivation on anxiety-like behavior in animal research: Systematic review and meta-analysis

Cited by 58 publications

References 91 publications

Revealing the role of the endocannabinoid system modulators, SR141716A, URB597 and VDM-11, in sleep homeostasis

Revealing the role of the endocannabinoid system modulators, SR141716A, URB597 and VDM-11, in sleep homeostasis

Brain Microdialysate Monoamines in Relation to Circadian Rhythms, Sleep, and Sleep Deprivation – a Systematic Review, Network Meta-analysis, and New Primary Data

The role of adenosine receptors in mood and anxiety disorders

Contact Info

Product

Resources

About